Weekly Digest – March 2025 Weekly Digest – March 2025 05 Mar 2025: Celltrion receives FDA Phase 1 IND approval for next-generation ADC Drug ‘CT-P70’ Celltrion received FDA approval for an Investigational New Drug (IND) application for its antibody-drug conjugate […]
Weekly Digest – March 2025 Weekly Digest – March 2025 28 Feb 2025: Enhertu recommended for approval in the EU by CHMP for patients with HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy Enhertu has been […]
Weekly Digest – March 2025 Weekly Digest – March 2025 03 March 2025: Callio Therapeutics launches with US$187 Million series A to advance multi-payload Antibody-Drug Conjugate platform through clinical proof-of-concept Callio Therapeutics launches with $187M Series A financing led by […]
Weekly Digest – March 2025 Weekly Digest – March 2025 03 March 2025: ENHERTU demonstrated statistically significant and clinically meaningful improvement in overall survival in patients with HER2 positive metastatic gastric cancer at interim analysis of DESTINY-Gastric04 Phase 3 trial […]
Weekly Digest – March 2025 Weekly Digest – March 2025 03 March 2025: SOTIO unveils promising preclinical data on SOT109, a next-gen ADC targeting Cadherin-17 (CDH17) for colorectal cancer SOTIO Biotech presented the first preclinical data on SOT109, an antibody-drug […]
Weekly Digest – March 2025 Weekly Digest – March 2025 07 Mar 2025: PinoBio announces results of dual-payload ADC platform research PinoBio presented research at World ADC London 2025, demonstrating the superior efficacy of its dual-payload ADC platform compared to […]
